INHIBIKASE THERAPEUTICS

We are a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain. We filed two Investigational New Drug, or IND, applications with the U.S. Food and Drug Administration, or FDA, in the first quarter of 2019 for our lead asset candidate, IkT-148009. One IND is for the treatment of Parkinson’s Disease, while the second is for treatment of gastrointestinal, or GI, complications that arise as early symptoms of PD in patients.

(Note: In an S-1/A filing dated Nov. 2, 2020, the IPO’s size was cut to 1.36 million shares, down from 2.27 million shares in a previous filing. The price range remained the same at $10 to $12.)

General Information

Industry:

BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Employees:

2

Founded:

2010

Contact Information

Address:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Phone Number:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

View Prospectus:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Financial Information

Market Cap:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Revenues:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Net Income:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

IPO Profile

Symbol:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Exchange:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Shares (millions):

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Price range:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Est. $ Volume:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Manager / Joint Managers:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

CO-Managers:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Expected To Trade:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Day:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Quiet Period Expiration Date:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Lock-Up Period Expiration Date:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

SCOOP Rating:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Rating Change:

Lorem ipsum dolor sit amet, consectetur adipiscing elit.